The divestiture of rezafungin to Mundipharma, coupled with the reacquisition of CD388 rights and the substantial private placement financing, are positive developments for Cidara Therapeutics. These moves not only provide a significant cash infusion but also streamline its focus on promising treatments, likely leading to increased investor confidence and a positive short-term impact on its stock price.